Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.63 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.63 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.54 |
| ▸ | LAP3 | P28838 | 7/20 | 0.52 |
| ▸ | ANPEP | P15144 | 4/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL3720250 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL28750429 | 0.93 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL20362356 | 0.91 | — | — | |
| Leucine SCHEMBL2478164 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| Leucine SCHEMBL8568063 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| Leucine SCHEMBL25241602 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| D-Leucine SCHEMBL9100148 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| Leucine SCHEMBL8568060 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| D-Leucine SCHEMBL9449950 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| Leucine SCHEMBL175940 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382625-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | WILLOW LABORATORIES INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-11951186-B2 | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same | WILLOW LABORATORIES, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-115176155-A | Indicator compounds, devices including indicator compounds, and methods of making and using the same | 塞卡科实验室有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-4049032-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | Cercacor Laboratories, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20210121582-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | MASIMO LABORATORIES | 2021-04-29 | — | — | US | disclosed |
| WO-2021081404-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CERCACOR LABORATORIES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2021-04-13 | — | — | US | disclosed |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-07-05 | — | — | US | disclosed |
| US-9944674-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2018-04-17 | — | — | US | disclosed |
| EP-2697246-B1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-03-07 | — | — | EP | disclosed |
| US-20140038903-A1 | Selective Cysteine Protease Inhibitors and Uses Thereof | NEW WORLD LABORATORIES, INC. (CA) | 2014-02-06 | — | — | US | disclosed |
| WO-2012140500-A9 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| WO-2012140500-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-10-18 | — | — | WO | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| WO-2010133000-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| US-6133000-A | CONTINUOUS FEEDING OF CORYNEBACTERIUM CULTURE TO PRODUCE L-LYSINE | DEGUSSA-HULS AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| US-5770409-A | CONTINUOUSLY SUPPLYING SUCROSE OR GLUCOSE | DEGUSSA AKTIENGSELLSCHAFT (DE) | 1998-06-23 | — | — | US | disclosed |
| US-5133976-A | Biosynthesis | RHONE-POULENC SANTE (FR) | 1992-07-28 | — | — | US | disclosed |
| EP-0160794-B1 | CHICKEN FLAVORANTS AND THE PROCESSES FOR PREPARING THEM | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1988-06-29 | — | — | EP | disclosed |
| EP-0160794-A1 | Chicken flavorants and the processes for preparing them | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | SLC7A5 3433/4885SLC1A3 1489/4885SLC1A2 1020/4885 |
| US-20140038903-A1 | Selective Cysteine Protease Inhibitors and Uses Thereof | SERPINB1, SERPINE1, CASP5 | SLC7A5 1444/4885SLC1A3 2606/4885SLC1A2 2240/4885 |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, SERPINE1, CASP5 | SLC7A5 1444/4885SLC1A3 2606/4885SLC1A2 2240/4885 |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | SERPINB1, SERPINE1, CASP5 | SLC7A5 1343/4885SLC1A3 2440/4885SLC1A2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.